future of glp-1 drugs The revolution: What UAB researchers are discovering about how these work What is the pipeline for
Description
Don't let weight loss slow your hair growth
Clinical practice
This marked a turning point, shifting GLP-1 agonists from diabetes-focused therapies to primary obesity treatments
2024 Jan 4;14:1354689
On the basis of results of the most recent CVOTs (DAPA-HF, DAPA-CKD, EMPEROR-R), the FDA has approved dapagliflozin (2020) and empagliflozin (2021) to reduce risk for CV death and HF hospitalization in adults with HF and reduced ejection fraction regardless of whether they have diabetes [24, 25]
